⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 24, 2024Molecular Therapy — Methods & Clinical DevelopmentOpen Access

Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice

Hikari Okada Takeharu Sakamoto Kouki Nio Ying-Yi Li Kazuyuki Kuroki Saiho Sugimoto Tetsuro Shimakami Nobuhide Doi Masao Honda Motoharu Seiki Shuichi Kaneko Taro Yamashita

View Full Paper

Ask AI

Bookmark

Share

Abstract

The hepatitis B virus (HBV) infects many people worldwide. As HBV infection frequently leads to liver fibrosis and carcinogenesis, developing anti-HBV therapeutic drugs is urgent. Therapeutic drugs for preventing covalently closed circular DNA (cccDNA) production, which can eliminate HBV infection, are unavailable. The host factor dedicator of cytokinesis 11 (DOCK11) is involved in the synthesis and maintenance of HBV cccDNA

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Okada et al. (2024) studied this question.

synapsesocial.com/papers/68e637f1b6db6435875c9915 https://doi.org/10.1016/j.omtm.2024.101289

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Roles Played by DOCK11, a Guanine Nucleotide Exchange Factor, in HBV Entry and Persistence in Hepatocytes2024 · 4 citations
2DOCK11 promotes HBV cccDNA formation through a PARP1-dependent mechanismOriginal Research · 2026
3Hepatitis B Virus Utilizes a Retrograde Trafficking Route via the Trans-Golgi Network to Avoid Lysosomal DegradationOriginal Research · 2022 · 17 citations
4Hepatitis B virus counters intracellular antiviral responses by saturating APOBEC/AID enzymes with rcDNA2024 · 1 citations
5Lipid Nanoparticle-Encapsulated TALEN-Encoding mRNA Inactivates Hepatitis B Virus Replication in Cultured Cells and Transgenic Mice2025 · 2 citations